- Home
- EXFY vs CCCC Comparison
EXFY vs CCCC Comparison
Compare EXFY & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- CCCC
- Stock Information
- Founded
- EXFY 2008
- CCCC 2015
- Country
- EXFY United States
- CCCC United States
- Employees
- EXFY N/A
- CCCC N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- CCCC Health Care
- Exchange
- EXFY Nasdaq
- CCCC Nasdaq
- Market Cap
- EXFY 343.4M
- CCCC 396.0M
- IPO Year
- EXFY 2021
- CCCC 2020
- Fundamental
- Price
- EXFY $3.31
- CCCC $3.85
- Analyst Decision
- EXFY Buy
- CCCC Buy
- Analyst Count
- EXFY 4
- CCCC 6
- Target Price
- EXFY $3.50
- CCCC $10.67
- AVG Volume (30 Days)
- EXFY 335.0K
- CCCC 2.0M
- Earning Date
- EXFY 02-20-2025
- CCCC 02-20-2025
- Dividend Yield
- EXFY N/A
- CCCC N/A
- EPS Growth
- EXFY N/A
- CCCC N/A
- EPS
- EXFY N/A
- CCCC N/A
- Revenue
- EXFY $137,440,000.00
- CCCC $33,668,000.00
- Revenue This Year
- EXFY N/A
- CCCC $75.79
- Revenue Next Year
- EXFY $6.09
- CCCC N/A
- P/E Ratio
- EXFY N/A
- CCCC N/A
- Revenue Growth
- EXFY N/A
- CCCC 65.45
- 52 Week Low
- EXFY $1.24
- CCCC $3.38
- 52 Week High
- EXFY $4.13
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- EXFY 47.16
- CCCC 47.04
- Support Level
- EXFY $3.07
- CCCC $3.81
- Resistance Level
- EXFY $3.68
- CCCC $4.07
- Average True Range (ATR)
- EXFY 0.17
- CCCC 0.27
- MACD
- EXFY -0.04
- CCCC 0.05
- Stochastic Oscillator
- EXFY 39.34
- CCCC 53.41
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.